Insider Trades45 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | Sell | MDGL | William John Sibold | President and CEO | 2,500 | $547.30 | $12.3B | -13.09% | +35.79% | $1.4M | -0.12% | — | Stalk |
| Jun 1, 2026 | Sell | MDGL | David Soergel | Chief Medical Officer | 1,042 | $495.74 | $12.3B | -13.09% | +35.79% | $516.6K | -9.41% | 10b5-1 | Stalk |
| May 18, 2026 | Sell | MDGL | David Soergel | Chief Medical Officer | 844 | $515.90 | $12.3B | -13.09% | +35.79% | $435.4K | -7.08% | — | Stalk |
| Mar 6, 2026 | Sell | MDGL | Shannon T Kelley | General Counsel | 360 | $431.94 | $12.3B | -13.09% | +35.79% | $155.5K | -2.05% | — | Stalk |
| Mar 6, 2026 | Sell | MDGL | Carole Huntsman | Chief Commercial Officer | 419 | $431.94 | $12.3B | -13.09% | +35.79% | $181.0K | -2.32% | — | Stalk |
| Mar 6, 2026 | Sell | MDGL | William John Sibold | President and CEO | 1,663 | $431.94 | $12.3B | -13.09% | +35.79% | $718.3K | -0.91% | — | Stalk |
| Mar 6, 2026 | Sell | MDGL | Mardi Dier | EVP and CFO | 1,982 | $430.87 | $12.3B | -13.09% | +35.79% | $854.0K | -1.20% | 10b5-1 | Stalk |
| Mar 2, 2026 | Sell | MDGL | Mardi Dier | EVP and CFO | 1,183 | $427.21 | $12.3B | -13.09% | +35.79% | $505.4K | -11.33% | — | Stalk |
| Jan 26, 2026 | Sell | MDGL | Carole Huntsman | Chief Commercial Officer | 910 | $493.78 | $12.3B | -13.09% | +35.79% | $449.3K | -4.61% | 10b5-1 | Stalk |
| Jan 26, 2026 | Sell | MDGL | William John Sibold | President and CEO | 1,577 | $492.42 | $12.3B | -13.09% | +35.79% | $776.5K | -1.05% | — | Stalk |
| Jan 20, 2026 | Sell | MDGL | Shannon T Kelley | General Counsel | 692 | $497.36 | $12.3B | -13.09% | +35.79% | $344.2K | -3.83% | 10b5-1 | Stalk |
| Dec 4, 2025 | Sell | MDGL | William John Sibold | President and CEO | 2,400 | $575.34 | $12.3B | -13.09% | +35.79% | $1.4M | -1.57% | — | Stalk |
| Dec 2, 2025 | Sell | MDGL | Mardi Dier | EVP and CFO | 8,346 | $414.99 | $12.3B | -13.09% | +35.79% | $3.5M | +0.00% | 10b5-1 | Stalk |
| Nov 21, 2025 | Sell | MDGL | Carole Huntsman | Chief Commercial Officer | 1,958 | $553.11 | $12.3B | -13.09% | +35.79% | $1.1M | -1.66% | 10b5-1 | Stalk |
| Sep 9, 2025 | Sell | MDGL | William John Sibold | President and CEO | 7,279 | $445.63 | $12.3B | -13.09% | +35.79% | $3.2M | -6.63% | — | Stalk |
| Aug 21, 2025 | Sell | MDGL | William John Sibold | President and CEO | 7,616 | $400.18 | $12.3B | -13.09% | +35.79% | $3.0M | -3.34% | 10b5-1 | Stalk |
| Aug 18, 2025 | Sell | MDGL | Shannon T Kelley | General Counsel | 1,304 | $367.81 | $12.3B | -13.09% | +35.79% | $479.6K | -1.67% | 10b5-1 | Stalk |
| Mar 10, 2025 | Sell | MDGL | Mardi Dier | SVP and CFO | 258 | $323.04 | $12.3B | -13.09% | +35.79% | $83.3K | -2.41% | 10b5-1 | Stalk |
| Mar 5, 2025 | Sell | MDGL | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | 28,226 | $214.41 | $12.3B | -13.09% | +35.79% | $6.1M | +0.00% | — | Stalk |
| Mar 3, 2025 | Sell | MDGL | Shannon T Kelley | General Counsel | 415 | $335.00 | $12.3B | -13.09% | +35.79% | $139.0K | -5.39% | 10b5-1 | Stalk |
| Mar 3, 2025 | Sell | MDGL | Carole Huntsman | Chief Commercial Officer | 1,834 | $325.98 | $12.3B | -13.09% | +35.79% | $597.8K | -2.09% | 10b5-1 | Stalk |
| Mar 3, 2025 | Sell | MDGL | Mardi Dier | SVP and CFO | 1,961 | $324.96 | $12.3B | -13.09% | +35.79% | $637.2K | -11.84% | 10b5-1 | Stalk |
| Feb 28, 2025 | Sell | MDGL | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | 1,227 | $341.07 | $12.3B | -13.09% | +35.79% | $418.5K | -13.85% | — | Stalk |
| Jan 24, 2025 | Sell | MDGL | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | 103 | $335.24 | $12.3B | -13.09% | +35.79% | $34.5K | -2.04% | — | Stalk |
| Jan 24, 2025 | Sell | MDGL | Carole Huntsman | Chief Commercial Officer | 347 | $335.24 | $12.3B | -13.09% | +35.79% | $116.3K | -3.22% | — | Stalk |
| Jan 24, 2025 | Sell | MDGL | Rebecca Taub | Pres., R&D, and CMO | 648 | $335.24 | $12.3B | -13.09% | +35.79% | $217.2K | -0.14% | — | Stalk |
| Jan 24, 2025 | Sell | MDGL | William John Sibold | President and CEO | 1,584 | $335.24 | $12.3B | -13.09% | +35.79% | $531.0K | -2.83% | — | Stalk |
| Jan 17, 2025 | Sell | MDGL | Shannon T Kelley | General Counsel | 277 | $273.41 | $12.3B | -13.09% | +35.79% | $75.7K | -3.47% | — | Stalk |
| Jan 17, 2025 | Sell | MDGL | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | 442 | $273.41 | $12.3B | -13.09% | +35.79% | $120.8K | -8.04% | — | Stalk |
| Jan 17, 2025 | Sell | MDGL | Rebecca Taub | Pres., R&D, and CMO | 1,689 | $273.41 | $12.3B | -13.09% | +35.79% | $461.8K | -0.37% | — | Stalk |
| Nov 21, 2024 | Sell | MDGL | Carole Huntsman | Chief Commercial Officer | 688 | $316.92 | $12.3B | -13.09% | +35.79% | $218.0K | -6.00% | — | Stalk |
| Sep 9, 2024 | Sell | MDGL | William John Sibold | President and CEO | 6,363 | $243.83 | $12.3B | -13.09% | +35.79% | $1.6M | -10.22% | — | Stalk |
| Jun 14, 2024 | Sell | MDGL | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | 3,800 | $183.54 | $12.3B | -13.09% | +35.79% | $697.5K | +0.00% | — | Stalk |
| Jun 12, 2024 | Sell | MDGL | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | 4,000 | $186.46 | $12.3B | -13.09% | +35.79% | $745.8K | +0.00% | — | Stalk |
| May 21, 2024 | Sell | MDGL | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | 1,036 | $231.34 | $12.3B | -13.09% | +35.79% | $239.7K | -15.85% | — | Stalk |
| Apr 8, 2024 | Sell | MDGL | Rebecca Taub | Pres., R&D, and CMO | 5,352 | $127.72 | $12.3B | -13.09% | +35.79% | $683.5K | +0.00% | 10b5-1 | Stalk |
| Apr 3, 2024 | Sell | MDGL | Rebecca Taub | Pres., R&D, and CMO | 147,776 | $126.68 | $12.3B | -13.09% | +35.79% | $18.7M | +0.00% | 10b5-1 | Stalk |
| Jan 16, 2024 | Sell | MDGL | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | 550 | $243.92 | $12.3B | -13.09% | +35.79% | $134.2K | -9.71% | — | Stalk |
| Jan 16, 2024 | Sell | MDGL | Brian Joseph Lynch | SVP and General Counsel | 949 | $243.92 | $12.3B | -13.09% | +35.79% | $231.5K | -6.33% | — | Stalk |
| Jan 16, 2024 | Sell | MDGL | Alex G. Howarth | Chief Financial Officer | 1,067 | $243.92 | $12.3B | -13.09% | +35.79% | $260.3K | -7.11% | — | Stalk |
| Jan 16, 2024 | Sell | MDGL | Rebecca Taub | Pres., R&D, and CMO | 1,546 | $243.92 | $12.3B | -13.09% | +35.79% | $377.1K | -9.34% | — | Stalk |
| Dec 14, 2023 | Sell | MDGL | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | 8,000 | $161.71 | $12.3B | -13.09% | +35.79% | $1.3M | +0.00% | — | Stalk |
| Dec 12, 2023 | Sell | MDGL | Robert E. Waltermire | Senior VP, Chief Pharma Dev. | 7,600 | $155.37 | $12.3B | -13.09% | +35.79% | $1.2M | +0.00% | — | Stalk |
| Dec 4, 2023 | Sell | MDGL | Brian Joseph Lynch | SVP and General Counsel | 5,600 | $152.58 | $12.3B | -13.09% | +35.79% | $854.5K | +0.00% | — | Stalk |
| Nov 29, 2023 | Sell | MDGL | Brian Joseph Lynch | SVP and General Counsel | 14,000 | $137.62 | $12.3B | -13.09% | +35.79% | $1.9M | +0.00% | — | Stalk |